Closely watched Pfizer lung cancer drug falls short in clinical trial Expectations had been high that sigvotatug vedotin could replace a widely used chemotherapy

https://www.statnews.com/2026/06/22/pfizer-lung-cancer-sigvotatug-vedotin/?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz-9x5Wdo69XtVtG4W1vdTP7Vhp8FpvWd5O-heCg0Zx4gapNlaozW6V-7-9rf3rrBWSRsNLh3oAs7eGGsO4_WpD_nNh4kWA&_hsmi=425127210&utm_content=425127210&utm_source=hs_email By Matthew HerperJune 22, 2026 Senior Writer, Medicine, Editorial Director of Events Pfizer's experimental drug for one the most common forms of lung cancer fell short in a clinical trial, serving a big blow to the company, which had positioned the treatment as a key growth driver. In the Phase 3 study, the drug, called sigvotatug vedotin, did not lead to a statistically significant improvement in overall survival over a chemotherapy called docetaxel. Pfizer acquired the therapy when it bought Seagen for $43 billion in 2023.